386 related articles for article (PubMed ID: 36198878)
1. Candida auris, a singular emergent pathogenic yeast: its resistance and new therapeutic alternatives.
Fernandes L; Ribeiro R; Henriques M; Rodrigues ME
Eur J Clin Microbiol Infect Dis; 2022 Dec; 41(12):1371-1385. PubMed ID: 36198878
[TBL] [Abstract][Full Text] [Related]
2. The Two-Component Response Regulator Ssk1 and the Mitogen-Activated Protein Kinase Hog1 Control Antifungal Drug Resistance and Cell Wall Architecture of Candida auris.
Shivarathri R; Jenull S; Stoiber A; Chauhan M; Mazumdar R; Singh A; Nogueira F; Kuchler K; Chowdhary A; Chauhan N
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055262
[No Abstract] [Full Text] [Related]
3. Intra-clade Heterogeneity in Candida auris: Risk of Management.
Fayed B; Lazreg IK; AlHumaidi RB; Qasem MAAA; Alajmy BMGN; Bojbarah FMAM; Senok A; Husseiny MI; Soliman SSM
Curr Microbiol; 2023 Jul; 80(9):295. PubMed ID: 37486431
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Differential Pathogenicity of Candida auris in a Galleria mellonella Infection Model.
Garcia-Bustos V; Ruiz-Saurí A; Ruiz-Gaitán A; Sigona-Giangreco IA; Cabañero-Navalon MD; Sabalza-Baztán O; Salavert-Lletí M; Tormo MÁ; Pemán J
Microbiol Spectr; 2021 Sep; 9(1):e0001321. PubMed ID: 34106570
[TBL] [Abstract][Full Text] [Related]
5. Comparative transcriptional analysis of
Jakab Á; Kovács F; Balla N; Nagy-Köteles C; Ragyák Á; Nagy F; Borman AM; Majoros L; Kovács R
Microbiol Spectr; 2024 Apr; 12(4):e0227823. PubMed ID: 38440972
[No Abstract] [Full Text] [Related]
6. Overview about Candida auris: What's up 12 years after its first description?
Desoubeaux G; Coste AT; Imbert C; Hennequin C
J Mycol Med; 2022 May; 32(2):101248. PubMed ID: 35091280
[TBL] [Abstract][Full Text] [Related]
7. Adenylyl Cyclase and Protein Kinase A Play Redundant and Distinct Roles in Growth, Differentiation, Antifungal Drug Resistance, and Pathogenicity of
Kim JS; Lee KT; Lee MH; Cheong E; Bahn YS
mBio; 2021 Oct; 12(5):e0272921. PubMed ID: 34663094
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic Therapy Is Effective Against
Bapat PS; Nobile CJ
Front Cell Infect Microbiol; 2021; 11():713092. PubMed ID: 34540717
[TBL] [Abstract][Full Text] [Related]
9. Candida auris Phenotypic Heterogeneity Determines Pathogenicity
Brown JL; Delaney C; Short B; Butcher MC; McKloud E; Williams C; Kean R; Ramage G
mSphere; 2020 Jun; 5(3):. PubMed ID: 32581078
[No Abstract] [Full Text] [Related]
10. Current global status of Candida auris an emerging multidrug-resistant fungal pathogen: bibliometric analysis and network visualization.
Ettadili H; Vural C
Braz J Microbiol; 2024 Mar; 55(1):391-402. PubMed ID: 38261261
[TBL] [Abstract][Full Text] [Related]
11. What do we know about the biology of the emerging fungal pathogen of humans Candida auris?
Bravo Ruiz G; Lorenz A
Microbiol Res; 2021 Jan; 242():126621. PubMed ID: 33096325
[TBL] [Abstract][Full Text] [Related]
12. Comparing the virulence of four major clades of Candida auris strains using a silkworm infection model: Clade IV isolates had higher virulence than the other clades.
Kurakado S; Matsumoto Y; Sugita T
Med Mycol; 2023 Nov; 61(11):. PubMed ID: 37898558
[TBL] [Abstract][Full Text] [Related]
13. Prospective Medicines against the Widespread, Emergent, and Multidrugresistant Opportunistic Fungal Pathogen Candida auris: A Breath of Hope.
Ramos LS; Silva LN; de Mello TP; Frota HF; Branquinha MH; Dos Santos ALS
Curr Top Med Chem; 2022; 22(16):1297-1305. PubMed ID: 35619311
[TBL] [Abstract][Full Text] [Related]
14. Candida auris infection; diagnosis, and resistance mechanism using high-throughput sequencing technology: a case report and literature review.
Hong H; Ximing Y; Jinghan M; Al-Danakh A; Shujuan P; Ying L; Yuting Y; Yuehong L; Xingwei Y
Front Cell Infect Microbiol; 2023; 13():1211626. PubMed ID: 38145050
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of dihydrofolate reductase from the emerging pathogenic fungus Candida auris.
Kirkman T; Sketcher A; de Morais Barroso V; Ishida K; Tosin M; Dias MVB
Acta Crystallogr D Struct Biol; 2023 Aug; 79(Pt 8):735-745. PubMed ID: 37428844
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.
Larkin E; Hager C; Chandra J; Mukherjee PK; Retuerto M; Salem I; Long L; Isham N; Kovanda L; Borroto-Esoda K; Wring S; Angulo D; Ghannoum M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223375
[No Abstract] [Full Text] [Related]
17. Drosophila melanogaster as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen Candida auris.
Wurster S; Albert ND; Kontoyiannis DP
Methods Mol Biol; 2022; 2517():299-316. PubMed ID: 35674964
[TBL] [Abstract][Full Text] [Related]
18. Current scenario of the search for new antifungal agents to treat Candida auris infections: An integrative review.
de Moraes DC
J Mycol Med; 2022 Mar; 32(1):101232. PubMed ID: 34883404
[TBL] [Abstract][Full Text] [Related]
19. Tools and techniques to identify, study, and control Candida auris.
Carty J; Chowdhary A; Bernstein D; Thangamani S
PLoS Pathog; 2023 Oct; 19(10):e1011698. PubMed ID: 37856418
[TBL] [Abstract][Full Text] [Related]
20. Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen.
Dekkerová J; Lopez-Ribot JL; Bujdáková H
Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):101-108. PubMed ID: 30327897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
